[go: up one dir, main page]

DK2016198T3 - Method for predicting a risk of adverse drug reacting by determination of hla-b 1502 - Google Patents

Method for predicting a risk of adverse drug reacting by determination of hla-b 1502

Info

Publication number
DK2016198T3
DK2016198T3 DK07797432.7T DK07797432T DK2016198T3 DK 2016198 T3 DK2016198 T3 DK 2016198T3 DK 07797432 T DK07797432 T DK 07797432T DK 2016198 T3 DK2016198 T3 DK 2016198T3
Authority
DK
Denmark
Prior art keywords
hla
predicting
risk
determination
adverse drug
Prior art date
Application number
DK07797432.7T
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Shuen-Lu Hung
Chih-Lung Shen
Chi-Feng Chang
Hsin-Yu Lin
Wei-Hsuan Chen
Original Assignee
Academia Sinica
Pharmigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38694734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2016198(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Academia Sinica, Pharmigene Inc filed Critical Academia Sinica
Application granted granted Critical
Publication of DK2016198T3 publication Critical patent/DK2016198T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/142Toxicological screening, e.g. expression profiles which identify toxicity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK07797432.7T 2006-05-11 2007-05-11 Method for predicting a risk of adverse drug reacting by determination of hla-b 1502 DK2016198T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80012106P 2006-05-11 2006-05-11
PCT/US2007/068782 WO2007134235A2 (en) 2006-05-11 2007-05-11 Hla alleles associated with adverse drug reactions and methods for detecting such

Publications (1)

Publication Number Publication Date
DK2016198T3 true DK2016198T3 (en) 2013-07-15

Family

ID=38694734

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07797432.7T DK2016198T3 (en) 2006-05-11 2007-05-11 Method for predicting a risk of adverse drug reacting by determination of hla-b 1502

Country Status (17)

Country Link
US (2) US7943309B2 (da)
EP (1) EP2016198B1 (da)
JP (1) JP2009536828A (da)
KR (1) KR101450348B1 (da)
CN (1) CN101454462A (da)
AU (1) AU2007249225B2 (da)
BR (1) BRPI0710436A8 (da)
CA (1) CA2651954C (da)
DK (1) DK2016198T3 (da)
ES (1) ES2422735T3 (da)
IL (1) IL194900A (da)
MY (1) MY150648A (da)
NZ (2) NZ597628A (da)
PL (1) PL2016198T3 (da)
PT (1) PT2016198E (da)
TW (1) TWI335937B (da)
WO (1) WO2007134235A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1536021A1 (en) * 2003-11-27 2005-06-01 Consortium National de Recherche en Genomique (CNRG) Method for HLA typing
TWI498461B (zh) 2010-04-12 2015-09-01 Univ Nat Yang Ming 利用人類白血球抗原(hla)篩檢預測藥物不良反應之方法
JP5959634B2 (ja) * 2011-06-23 2016-08-02 チャン グン メディカル ファンデーション チャン グン メモリアル ホスピタル アット キールン フェニトインによって誘発される薬の副作用のリスク評価
CN102296109A (zh) * 2011-06-30 2011-12-28 北京思尔成生物技术有限公司 HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒
US20150225788A1 (en) 2011-12-12 2015-08-13 Wen-Hung Chung Risk assessment for phenytoin-induced adverse drug reactions
CN102660635B (zh) * 2012-01-14 2014-03-12 长沙三济生物科技有限公司 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒
CN103114138B (zh) * 2013-01-27 2014-12-03 复旦大学 Pcr-ssp法定性检测hla-b*1502基因的方法及临床试剂盒
US10041121B2 (en) * 2013-09-17 2018-08-07 Agency For Science, Technology And Research Method for detection of a genetic variant
CN104017898B (zh) * 2014-06-25 2016-04-27 上海荻硕贝肯生物科技有限公司 快速检测hla-b*5801等位基因的引物、试剂盒及方法
CN104232781B (zh) * 2014-09-26 2017-04-19 陕西佰美基因股份有限公司 一种检测HLA‑B*5801等位基因的TaqMan探针实时荧光PCR方法
CN106119362B (zh) * 2016-06-30 2019-09-10 江苏伟禾生物科技有限公司 一种用于检测hla-b*1502等位基因的引物组及试剂盒
CN108929902B (zh) * 2018-07-28 2022-03-25 北京博奥晶典生物技术有限公司 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法
CN109355358A (zh) * 2018-10-22 2019-02-19 江苏美因康生物科技有限公司 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法
CN109554460B (zh) * 2018-12-17 2022-03-22 上海市疾病预防控制中心 一种基于hla基因多态性位点预测h7n9易感人群的检测方法及其用途
TWI804620B (zh) * 2019-05-06 2023-06-11 長庚醫療財團法人林口長庚紀念醫院 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途
US20220259655A1 (en) * 2019-05-06 2022-08-18 Chang Gung Memorial Hospital, Linkou Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof
CN111620924A (zh) * 2020-06-04 2020-09-04 华中农业大学 基于天然产物的药物设计方法、五环三萜类化合物、其制备方法及应用
CN113308532A (zh) * 2021-05-28 2021-08-27 上海康黎诊断技术有限公司 一种用于检测人hla-b*1502基因突变的特异性引物探针组合及其试剂盒,以及方法
WO2023080478A1 (ko) * 2021-11-02 2023-05-11 주식회사 랩 지노믹스 Hla-b*5801 대립유전자 검출용 핵산 분자 및 이를 이용한 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583238A (en) * 1990-11-19 1996-12-10 G. D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
EP0689609B2 (en) * 1993-03-18 2005-04-13 N.V. Innogenetics S.A. Process for typing hla-b using specific primers and probes sets
US5550039A (en) * 1995-03-07 1996-08-27 Hoffmann-La Roche Inc. Oligonucleotide primers for HLA class I B locus DNA typing
US6583139B1 (en) * 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US7638510B2 (en) * 2003-02-17 2009-12-29 Novartis Ag Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions

Also Published As

Publication number Publication date
WO2007134235A2 (en) 2007-11-22
JP2009536828A (ja) 2009-10-22
BRPI0710436A8 (pt) 2018-06-26
EP2016198B1 (en) 2013-05-01
KR101450348B1 (ko) 2014-10-14
CN101454462A (zh) 2009-06-10
TWI335937B (en) 2011-01-11
WO2007134235A3 (en) 2008-01-17
EP2016198A2 (en) 2009-01-21
MY150648A (en) 2014-02-14
PT2016198E (pt) 2013-07-29
AU2007249225B2 (en) 2013-06-27
IL194900A0 (en) 2009-08-03
US20110212439A1 (en) 2011-09-01
IL194900A (en) 2013-02-28
ES2422735T3 (es) 2013-09-13
TW200844238A (en) 2008-11-16
BRPI0710436A2 (pt) 2012-10-09
PL2016198T3 (pl) 2013-12-31
KR20090031671A (ko) 2009-03-27
US8142999B2 (en) 2012-03-27
US7943309B2 (en) 2011-05-17
NZ597628A (en) 2013-07-26
NZ572259A (en) 2012-03-30
EP2016198A4 (en) 2010-07-21
US20080145846A1 (en) 2008-06-19
CA2651954A1 (en) 2007-11-22
AU2007249225A1 (en) 2007-11-22
CA2651954C (en) 2014-02-25

Similar Documents

Publication Publication Date Title
DK2016198T3 (en) Method for predicting a risk of adverse drug reacting by determination of hla-b 1502
IL189690A0 (en) A method for evaluation of a gemstone
IL179344A (en) Mobile Platform Tracking Method
PL2029967T3 (pl) Sposób pomiaru przedmiotu
ZA200903889B (en) Process for the synthesis of moxifloxacin hydrochloride
AP2786A (en) A method of agglomeration
EP1928209A4 (en) METHOD FOR MANUFACTURING A SPEAKER
ZA200804555B (en) A method for production of a coated endovascular device
PL2043811T3 (pl) Sposób wytwarzania części obiciowej
IL198259A0 (en) Process for the sulfinylation of a pyrazole derivative
SG131081A1 (en) Method for separating parts from a substrate
IL181484A0 (en) A method for evaluation of a gemstone
EP1889002A4 (en) Diffraction method for measuring the thickness of a working part
ZA200808830B (en) A method of depicting an image
IL198260A0 (en) Process for the sulfinylation of a pyrazole derivative
GB0604660D0 (en) Assay for phospholipidosis
EP2081576A4 (en) METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES
GB2456690B (en) A method for quantitative detection of diabetes related immunological markers
IL194459A0 (en) A method for assaying antigens
EP2011001A4 (en) METHOD FOR DETERMINING THE MOST PROBABLE K LOCATION
FI20060916L (fi) Menetelmä kauraa sisältävän taikinan valmistamiseksi
GB0621886D0 (en) Method for making a shoe
GB0712702D0 (en) A method for providing measurement gaps
TWI317857B (en) Method for updating the timing of a baseboard management controller
IL195058A0 (en) Duloxetine hcl polymorphs